ABCL AbCellera Biologics Inc.

Nasdaq Pharmaceutical Preparations A1 CIK: 0001703057
AI RATING
SELL
68% Confidence

Investment Thesis

AbCellera demonstrates strong balance sheet fundamentals with $938.1M equity and zero debt, enabling a 14.05x current ratio. However, the company burns $33.5M quarterly in operating cash flow against only $77.1M cash reserves, creating a critical 2-3 quarter runway without additional financing. Despite encouraging 160.6% revenue growth, absolute revenue of $8.3M cannot justify the operational burn rate, indicating years to profitability without significant pipeline value realization or capital raises.

Strengths

  • + Zero debt with strong 938.1M stockholders equity cushion
  • + Excellent liquidity position (14.05x current ratio) for operational flexibility
  • + Robust revenue growth of 160.6% YoY demonstrates traction with customers

Risks

  • ! Critical cash runway of only 2-3 quarters at current $33.5M quarterly burn rate
  • ! Negative free cash flow of -$37.4M with no visible profitability timeline
  • ! Inevitable shareholder dilution from required capital raises before achieving positive cash flow

Key Metrics to Watch

Financial Metrics

Revenue
8.3M
Net Income
-43.2M
EPS (Diluted)
$-0.14
Free Cash Flow
-37.4M
Total Assets
1.3B
Cash
77.1M

Profitability Ratios

Gross Margin N/A
Operating Margin -691.7%
Net Margin -519.1%
ROE -4.6%
ROA -3.3%
FCF Margin -449.2%

Balance Sheet & Liquidity

Current Ratio
14.05x
Quick Ratio
13.89x
Debt/Equity
0.00x
Debt/Assets
28.2%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-13T07:37:31.018900 | Data as of: 2026-03-31 | Powered by Claude AI